亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

深圳石金谷科技有限公司  

化學合成原料藥、醫藥中間體、化工原料、香精香料、食品輔料、植物提取物

搜索
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人:劉艷平
  • 電話:0755-61930350
  • 郵件:sz09@yccreate.com
  • 傳真:0755-84556470
  • QQ:2355880511
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 廣東深圳格列吡嗪原料藥廠家
廣東深圳格列吡嗪原料藥廠家
單價 面議對比
詢價 暫無
發貨 廣東深圳市付款后3天內
品牌 南箭
型號 29094-61-9
規格 醫藥級
過期 長期有效
更新 2013-08-13 11:00
 
詳細信息
廣東深圳格列吡嗪原料藥廠家
格列吡嗪

中文別名:1-環己基-3-{4-[2-(5-甲基吡嗪-2-酰胺)-乙基]苯磺酰}脲;格列吡嗪;格列甲嗪 ( 格列吡嗪 );吡磺環己脲;刺玫果皂甙提取物
CAS號:29094-61-9
分子量:445.54
分子式:C21H27N5O4S
格列吡嗪 Glipizide
CAS號:29094-61-9 
化學名: 1-環己基-3-{4-[2-(5-甲基吡嗪-2-酰胺)-乙基]苯磺酰}脲 
其它名稱: N-[2-[4-[[[(Cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]5-methylpyrazinecarboxamide 
分子式: C21H27N5O4S 
分子量: 445.54 
分子結構式: 
外觀 : 白色或類白色結晶性粉末. 
適應癥: 2型糖尿病. 
©2025 深圳石金谷科技有限公司 版權所有   技術支持:化工網   訪問量:28568  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |